Pharsight

Drug Patents Expiring in 2020

1. Adlyxin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE45313 SANOFI-AVENTIS US Exendin variant peptides
Jul, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 27, 2021

Drugs and Companies using LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 27 July, 2016

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

ADLYXIN family patents

Family Patents

2. Arcapta Neohaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8796307 NOVARTIS Beta2-adrenoreceptor agonists
Jun, 2020

(3 years ago)

US8658673 NOVARTIS BETA2-adrenoreceptor agonists
Jun, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 01, 2016

Drugs and Companies using INDACATEROL MALEATE ingredient

NCE-1 date: 02 July, 2015

Market Authorisation Date: 01 July, 2011

Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema

Dosage: POWDER;INHALATION

More Information on Dosage

ARCAPTA NEOHALER family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Axumin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5808146 BLUE EARTH Amino acid analogs for tumor imaging
Nov, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 27, 2021

Drugs and Companies using FLUCICLOVINE F-18 ingredient

NCE-1 date: 27 May, 2020

Market Authorisation Date: 27 May, 2016

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

AXUMIN family patents

Family Patents

4. Bevyxxa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6835739 PORTOLA PHARMS INC Benzamides and related inhibitors of factor Xa
Sep, 2020

(3 years ago)

US8691847 PORTOLA PHARMS INC Benzamides and related inhibitors of factor Xa
Sep, 2020

(3 years ago)

US6376515 PORTOLA PHARMS INC Benzamides and related inhibitors of factor Xa
Sep, 2020

(3 years ago)

US8518977 PORTOLA PHARMS INC Benzamides and related inhibitors of factor XA
Sep, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 23, 2022

Drugs and Companies using BETRIXABAN ingredient

NCE-1 date: 23 June, 2021

Market Authorisation Date: 23 June, 2017

Treatment: Prophylaxis of venous thromboembolism; Preventing condition characterized by undesired thrombosis

Dosage: CAPSULE;ORAL

More Information on Dosage

BEVYXXA family patents

Family Patents

5. Bydureon patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jan 22, 2025
New Patient Population(NPP) Jul 22, 2024
M(M-240) Feb 15, 2022
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
New Product(NP) Jan 27, 2015

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON family patents

Family Patents

6. Bydureon Pen patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jan 22, 2025
New Patient Population(NPP) Jul 22, 2024
M(M-240) Feb 15, 2022
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
New Product(NP) Jan 27, 2015

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON PEN family patents

Family Patents

7. Caplyta patents expiration

Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE39680 INTRA-CELLULAR Substituted heterocycle fused gamma-carbolines
Jun, 2020

(3 years ago)

US7183282 INTRA-CELLULAR Substituted heterocycle fused γ-carbolines
Jun, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 20, 2024
New Indication(I-882) Dec 17, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 21 December, 2023

Market Authorisation Date: 22 April, 2022

Treatment: Treatment of schizophrenia

Dosage: CAPSULE;ORAL

More Information on Dosage

CAPLYTA family patents

Family Patents

8. Cresemba patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7459561 ASTELLAS N-substituted carbamoyloxyalkyl-azolium derivatives
Oct, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-90) Mar 06, 2022
New Chemical Entity Exclusivity(NCE) Mar 06, 2020
Orphan Drug Exclusivity(ODE-305) Mar 06, 2022
Orphan Drug Exclusivity(ODE-453) Dec 08, 2030
New Patient Population(NPP) Dec 08, 2026
Orphan Drug Exclusivity(ODE-459) Dec 08, 2030
Pediatric Exclusivity(PED) Jun 08, 2031
Generating Antibiotic Incentives Now(GAIN) Sep 06, 2027
Orphan Drug Exclusivity(ODE) Mar 06, 2022

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

NCE-1 date: 08 June, 2030

Market Authorisation Date: 06 March, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS; CAPSULE;ORAL

More Information on Dosage

CRESEMBA family patents

Family Patents

9. Daliresp patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5712298 ASTRAZENECA Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
Jan, 2020

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-208) Aug 31, 2020
New Strength(NS) Jan 23, 2021
New Dosing Schedule(D-171) Jan 23, 2021
New Chemical Entity Exclusivity(NCE) Feb 28, 2016

Drugs and Companies using ROFLUMILAST ingredient

NCE-1 date: 28 February, 2015

Market Authorisation Date: 23 January, 2018

Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations

Dosage: TABLET;ORAL

How can I launch a generic of DALIRESP before it's drug patent expiration?
More Information on Dosage

DALIRESP family patents

Family Patents

10. Dexilant patents expiration

Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9145389 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 30, 2012
New Patient Population(NPP) Jul 08, 2019
Pediatric Exclusivity(PED) Jul 30, 2012

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage

DEXILANT family patents

Family Patents

11. Dexilant Solutab patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6462058 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

US9145389 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

US7285668 TAKEDA PHARMS USA Process for the crystallization of (R)- or (S)-lansoprazole
Jun, 2020

(3 years ago)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 26 January, 2016

Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage

DEXILANT SOLUTAB family patents

Family Patents

12. Duaklir Pressair patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7078412 COVIS Quinuclidine derivatives and medicinal compositions containing the same
Jul, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Mar 29, 2022

Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

DUAKLIR PRESSAIR family patents

Family Patents

13. Eligard Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9914802 TOLMAR Sustained release polymer
Nov, 2020

(3 years ago)

US9539333 TOLMAR Sustained release polymer
Nov, 2020

(3 years ago)

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 14 December, 2004

Treatment: Palliative treatment of prostate cancer; Method of treating cancer

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

ELIGARD KIT family patents

Family Patents

14. Farxiga patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
M(M-238) Feb 22, 2022
New Indication(I-834) May 05, 2023
M(M-212) Oct 20, 2020
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-157) Mar 11, 2018
New Indication(I-841) Oct 18, 2022

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

15. Fensolvi Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9914802 TOLMAR Sustained release polymer
Nov, 2020

(3 years ago)

US9539333 TOLMAR Sustained release polymer
Nov, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-829) May 01, 2023

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 01 May, 2020

Treatment: Method of treating pediatric patients 2 years of age and older with central precocious puberty

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

FENSOLVI KIT family patents

Family Patents

16. Feraheme patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8926947 COVIS Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
Mar, 2020

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 30, 2012
New Indication(I-767) Feb 02, 2021

Drugs and Companies using FERUMOXYTOL ingredient

Market Authorisation Date: 30 June, 2009

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of FERAHEME before it's drug patent expiration?
More Information on Dosage

FERAHEME family patents

Family Patents

17. Juxtapid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5712279 CHIESI Inhibitors of microsomal triglyceride transfer protein and method
Feb, 2020

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Dec 21, 2019
New Chemical Entity Exclusivity(NCE) Dec 21, 2017
Orphan Drug Exclusivity(ODE-36) Dec 21, 2019

Drugs and Companies using LOMITAPIDE MESYLATE ingredient

NCE-1 date: 21 December, 2016

Market Authorisation Date: 21 December, 2012

Treatment: Treatment of hypercholesterolemia, hyperlipidemia and hyperlipoproteinemia in patients with homozygous familial hypercholesterolemia

Dosage: CAPSULE;ORAL

More Information on Dosage

JUXTAPID family patents

Family Patents

18. Luzu patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5900488 BAUSCH Method for treating mycosis using imidazolylacetonitrile derivatives
Jan, 2020

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 14, 2018
New Patient Population(NPP) Feb 20, 2021

Drugs and Companies using LULICONAZOLE ingredient

NCE-1 date: 14 November, 2017

Market Authorisation Date: 14 November, 2013

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage

LUZU family patents

Family Patents

19. Nuplazid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7858789 ACADIA PHARMS INC Derivatives of 4-aminopiperidine and their use as a medicament
Dec, 2020

(3 years ago)

US8110574 ACADIA PHARMS INC Derivatives of 4-aminopiperidine and their use as a medicament
Dec, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 29, 2021

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

NCE-1 date: 29 April, 2020

Market Authorisation Date: 28 June, 2018

Treatment: NA

Dosage: TABLET;ORAL; CAPSULE;ORAL

How can I launch a generic of NUPLAZID before it's drug patent expiration?
More Information on Dosage

NUPLAZID family patents

Family Patents

20. Orbactiv patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5840684 MELINTA THERAP Glycopeptide antibiotic derivatives
Nov, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 06, 2019
Generating Antibiotic Incentives Now(GAIN) Aug 06, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 07 August, 2023

Market Authorisation Date: 06 August, 2014

Treatment: Treatment of bacterial skin and skin structure infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ORBACTIV family patents

Family Patents

21. Qtern patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-175) Apr 05, 2019
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
New Combination(NC) Feb 27, 2020
New Strength(NS) May 02, 2022
New Indication(I-804) May 02, 2022

Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 02 May, 2019

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET;ORAL

How can I launch a generic of QTERN before it's drug patent expiration?
More Information on Dosage

QTERN family patents

Family Patents

22. Qternmet Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 02, 2022

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 02 May, 2019

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

QTERNMET XR family patents

Family Patents

23. Soliqua 100/33 patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE45313 SANOFI-AVENTIS US Exendin variant peptides
Jul, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Nov 21, 2019
New Chemical Entity Exclusivity(NCE) Jul 27, 2021

Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 21 November, 2016

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

SOLIQUA 100/33 family patents

Family Patents

24. Varithena patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8323677 PROVENSIS Therapeutic foam
May, 2020

(3 years ago)

US8734833 PROVENSIS Therapeutic foam
May, 2020

(3 years ago)

US7604185 PROVENSIS Generation of therapeutic microfoam
May, 2020

(3 years ago)

Drugs and Companies using POLIDOCANOL ingredient

Market Authorisation Date: 21 December, 2017

Treatment: A method of using a sclerosing agent for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous (gsv) system above and below the ...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

VARITHENA family patents

Family Patents

25. Vascepa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8188146 AMARIN PHARMS Highly purified ethyl EPA and other EPA derivatives
Jan, 2020

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 26, 2017
New Indication(I-819) Dec 13, 2022
New Product(NP) Jul 26, 2015

Drugs and Companies using ICOSAPENT ETHYL ingredient

NCE-1 date: 26 July, 2016

Market Authorisation Date: 26 July, 2012

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of VASCEPA before it's drug patent expiration?
More Information on Dosage

VASCEPA family patents

Family Patents

26. Velphoro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6174442 VIFOR FRESENIUS Adsorbent for phosphate from an aqueous medium, production and use of said adsorbent
Jun, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 27, 2016

Drugs and Companies using FERRIC OXYHYDROXIDE ingredient

Market Authorisation Date: 27 November, 2013

Treatment: Control of phosphorous levels in patients

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage

VELPHORO family patents

Family Patents

27. Wakix patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7169928 HARMONY Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications
Feb, 2020

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 14, 2024
Orphan Drug Exclusivity(ODE-255) Aug 14, 2026
Orphan Drug Exclusivity(ODE-331) Oct 13, 2027
New Indication(I-846) Oct 13, 2023

Drugs and Companies using PITOLISANT HYDROCHLORIDE ingredient

NCE-1 date: 15 August, 2023

Market Authorisation Date: 14 August, 2019

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

WAKIX family patents

Family Patents

28. Xarelto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7585860 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Dec, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-867) Aug 23, 2024
Pediatric Exclusivity(PED) Feb 23, 2025
New Indication(I-824) Oct 11, 2021
New Dosing Schedule(D-168) Oct 27, 2020
New Indication(I-810) Oct 11, 2022
M(M-284) Mar 10, 2023
New Indication(I-660) Nov 02, 2015
New Indication(I-661) Nov 02, 2015
New Indication(I-662) Nov 02, 2015
New Chemical Entity Exclusivity(NCE) Jul 01, 2016
New Indication(I-643) Nov 04, 2014

Drugs and Companies using RIVAROXABAN ingredient

NCE-1 date: 24 February, 2024

Market Authorisation Date: 11 October, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of XARELTO before it's drug patent expiration?
More Information on Dosage

XARELTO family patents

Family Patents

29. Xeljanz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7265221 PF PRISM CV Pyrrolo[2,3-d]pyrimidine compounds
Dec, 2020

(3 years ago)

US7301023 PF PRISM CV Chiral salt resolution
Dec, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-879) Dec 14, 2024
New Patient Population(NPP) Sep 25, 2023
New Indication(I-761) Dec 14, 2020
M(M-135) Feb 21, 2017
New Indication(I-780) May 30, 2021
New Chemical Entity Exclusivity(NCE) Nov 06, 2017

Drugs and Companies using TOFACITINIB CITRATE ingredient

NCE-1 date: 06 November, 2016

Market Authorisation Date: 06 November, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage

XELJANZ family patents

Family Patents

30. Xeljanz Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7301023 PFIZER Chiral salt resolution
Dec, 2020

(3 years ago)

US7265221 PFIZER Pyrrolo[2,3-d]pyrimidine compounds
Dec, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-879) Dec 14, 2024
New Indication(I-761) Dec 14, 2020
New Chemical Entity Exclusivity(NCE) Nov 06, 2017

Drugs and Companies using TOFACITINIB CITRATE ingredient

NCE-1 date: 06 November, 2016

Market Authorisation Date: 23 February, 2016

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of XELJANZ XR before it's drug patent expiration?
More Information on Dosage

XELJANZ XR family patents

Family Patents

31. Xigduo Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
New Indication(I-841) Oct 18, 2022
M(M-238) Feb 22, 2022

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 28 July, 2017

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of XIGDUO XR before it's drug patent expiration?
More Information on Dosage

XIGDUO XR family patents

Family Patents

List of large molecules

1. List of Opdivo large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US8008449 NA Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
Mar, 2020

(4 years ago)

Ingredients: NIVOLUMAB

2. List of Vectibix large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US6235883 NA Human monoclonal antibodies to epidermal growth factor receptor
Apr, 2020

(4 years ago)

Ingredients: PANITUMUMAB

3. List of Egrifta large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US5861379 NA Chimeric fatty body-pro-GRF analogs with increased biological potency
May, 2020

(3 years ago)

Ingredients: TESAMORELIN

4. List of Lucentis large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US6407213 NA Method for making humanized antibodies
Jun, 2020

(3 years ago)

Ingredients: RANIBIZUMAB